Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.55
LGND's Cash to Debt is ranked lower than
87% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. LGND: 0.55 )
Ranked among companies with meaningful Cash to Debt only.
LGND' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.50 Max: No Debt
Current: 0.55
Equity to Asset 0.64
LGND's Equity to Asset is ranked lower than
56% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. LGND: 0.64 )
Ranked among companies with meaningful Equity to Asset only.
LGND' s Equity to Asset Range Over the Past 10 Years
Min: -0.83  Med: 0.12 Max: 0.68
Current: 0.64
-0.83
0.68
Interest Coverage 3.30
LGND's Interest Coverage is ranked lower than
89% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. LGND: 3.30 )
Ranked among companies with meaningful Interest Coverage only.
LGND' s Interest Coverage Range Over the Past 10 Years
Min: 0.17  Med: 3.18 Max: 7.19
Current: 3.3
0.17
7.19
F-Score: 6
Z-Score: 6.65
M-Score: 0.46
WACC vs ROIC
8.30%
118.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 44.93
LGND's Operating margin (%) is ranked higher than
95% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. LGND: 44.93 )
Ranked among companies with meaningful Operating margin (%) only.
LGND' s Operating margin (%) Range Over the Past 10 Years
Min: -466.69  Med: -13.96 Max: 38
Current: 44.93
-466.69
38
Net-margin (%) 302.62
LGND's Net-margin (%) is ranked higher than
98% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. LGND: 302.62 )
Ranked among companies with meaningful Net-margin (%) only.
LGND' s Net-margin (%) Range Over the Past 10 Years
Min: -359.19  Med: 8.48 Max: 2184.64
Current: 302.62
-359.19
2184.64
ROE (%) 120.40
LGND's ROE (%) is ranked higher than
100% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. LGND: 120.40 )
Ranked among companies with meaningful ROE (%) only.
LGND' s ROE (%) Range Over the Past 10 Years
Min: -1046.55  Med: 31.67 Max: 997.71
Current: 120.4
-1046.55
997.71
ROA (%) 58.82
LGND's ROA (%) is ranked higher than
99% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. LGND: 58.82 )
Ranked among companies with meaningful ROA (%) only.
LGND' s ROA (%) Range Over the Past 10 Years
Min: -56.92  Med: 3.08 Max: 112.83
Current: 58.82
-56.92
112.83
ROC (Joel Greenblatt) (%) 1183.56
LGND's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. LGND: 1183.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LGND' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1252.88  Med: -89.87 Max: 6370.4
Current: 1183.56
-1252.88
6370.4
Revenue Growth (3Y)(%) 28.90
LGND's Revenue Growth (3Y)(%) is ranked higher than
82% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. LGND: 28.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LGND' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61  Med: 15.00 Max: 43.1
Current: 28.9
-61
43.1
EBITDA Growth (3Y)(%) 134.80
LGND's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. LGND: 134.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LGND' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.5  Med: -1.15 Max: 197.7
Current: 134.8
-68.5
197.7
» LGND's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

LGND Guru Trades in Q2 2015

Jim Simons 96,094 sh (New)
Ken Fisher 80,608 sh (-1.59%)
RS Investment Management 982,960 sh (-17.22%)
» More
Q3 2015

LGND Guru Trades in Q3 2015

RS Investment Management 1,379,230 sh (+40.31%)
Ken Fisher 70,683 sh (-12.31%)
Jim Simons 72,200 sh (-24.87%)
» More
Q4 2015

LGND Guru Trades in Q4 2015

Paul Tudor Jones 2,468 sh (New)
Jim Simons 174,300 sh (+141.41%)
Ken Fisher 70,583 sh (-0.14%)
RS Investment Management 1,089,730 sh (-20.99%)
» More
Q1 2016

LGND Guru Trades in Q1 2016

Joel Greenblatt 21,822 sh (New)
Columbia Wanger 158,034 sh (New)
Paul Tudor Jones 3,900 sh (+58.02%)
Ken Fisher 70,583 sh (unchged)
RS Investment Management 912,545 sh (-16.26%)
Jim Simons 116,800 sh (-32.99%)
» More
» Details

Insider Trades

Latest Guru Trades with LGND

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:AMGN, NAS:GILD, NAS:CELG, NAS:BIIB » details
Traded in other countries:LGDN.Germany,
Ligand Pharmaceuticals Inc is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.

Ligand Pharmaceuticals Inc was incorporated in Delaware in 1987. It is a biopharmaceutical company engaged in developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. The Company has evaluated ASC 280 and has identified two reportable segments: the development and commercialization of drugs using Captisol technology by CyDex Pharmaceuticals, Inc. and the biopharmaceutical company. With its portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, the Company offers investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. It has multiple partnered programs in its portfolio that are either in or nearing the regulatory approval process. GSKs Promacta (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP. The Company currently receives royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza. The drug is also marketed in Spain under the brand name Conbriza through a co-promotion with Almirall, an international pharmaceutical company based in Spain. The Company currently has no manufacturing facilities. It currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a supplier of active pharmaceutical ingredients, or APIs and API intermediates located in Portugal. Its competitive position also depends upon its ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales. The Company is subject to rigorous regulation by federal and various state authorities, including the FDA.

Ratios

vs
industry
vs
history
P/E(ttm) 10.02
LGND's P/E(ttm) is ranked higher than
86% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.15 vs. LGND: 10.02 )
Ranked among companies with meaningful P/E(ttm) only.
LGND' s P/E(ttm) Range Over the Past 10 Years
Min: 0.99  Med: 94.31 Max: 269.4
Current: 10.02
0.99
269.4
Forward P/E 22.99
LGND's Forward P/E is ranked lower than
63% of the 94 Companies
in the Global Biotechnology industry.

( Industry Median: 17.15 vs. LGND: 22.99 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 10.05
LGND's PE(NRI) is ranked higher than
86% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 30.43 vs. LGND: 10.05 )
Ranked among companies with meaningful PE(NRI) only.
LGND' s PE(NRI) Range Over the Past 10 Years
Min: 7.16  Med: 113.73 Max: 99999999.99
Current: 10.05
7.16
99999999.99
Price/Owner Earnings (ttm) 67.59
LGND's Price/Owner Earnings (ttm) is ranked lower than
58% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 37.01 vs. LGND: 67.59 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LGND' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 1.54  Med: 49.17 Max: 1246.25
Current: 67.59
1.54
1246.25
P/B 6.52
LGND's P/B is ranked lower than
75% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. LGND: 6.52 )
Ranked among companies with meaningful P/B only.
LGND' s P/B Range Over the Past 10 Years
Min: 5.26  Med: 21.46 Max: 174.72
Current: 6.52
5.26
174.72
P/S 30.56
LGND's P/S is ranked lower than
68% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. LGND: 30.56 )
Ranked among companies with meaningful P/S only.
LGND' s P/S Range Over the Past 10 Years
Min: 3.34  Med: 16.41 Max: 714.32
Current: 30.56
3.34
714.32
PFCF 81.82
LGND's PFCF is ranked lower than
80% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 26.95 vs. LGND: 81.82 )
Ranked among companies with meaningful PFCF only.
LGND' s PFCF Range Over the Past 10 Years
Min: 33.59  Med: 81.71 Max: 475.54
Current: 81.82
33.59
475.54
POCF 56.08
LGND's POCF is ranked lower than
77% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. LGND: 56.08 )
Ranked among companies with meaningful POCF only.
LGND' s POCF Range Over the Past 10 Years
Min: 21.96  Med: 63.07 Max: 3131.43
Current: 56.08
21.96
3131.43
EV-to-EBIT 67.79
LGND's EV-to-EBIT is ranked lower than
81% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. LGND: 67.79 )
Ranked among companies with meaningful EV-to-EBIT only.
LGND' s EV-to-EBIT Range Over the Past 10 Years
Min: -889.8  Med: -6.35 Max: 544.7
Current: 67.79
-889.8
544.7
EV-to-EBITDA 60.71
LGND's EV-to-EBITDA is ranked lower than
81% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. LGND: 60.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
LGND' s EV-to-EBITDA Range Over the Past 10 Years
Min: -226.2  Med: -4.50 Max: 816.4
Current: 60.71
-226.2
816.4
Shiller P/E 34.76
LGND's Shiller P/E is ranked higher than
74% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 51.13 vs. LGND: 34.76 )
Ranked among companies with meaningful Shiller P/E only.
LGND' s Shiller P/E Range Over the Past 10 Years
Min: 28.04  Med: 101.73 Max: 7692
Current: 34.76
28.04
7692
Current Ratio 10.87
LGND's Current Ratio is ranked higher than
78% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. LGND: 10.87 )
Ranked among companies with meaningful Current Ratio only.
LGND' s Current Ratio Range Over the Past 10 Years
Min: 0.28  Med: 1.72 Max: 12.94
Current: 10.87
0.28
12.94
Quick Ratio 10.73
LGND's Quick Ratio is ranked higher than
78% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. LGND: 10.73 )
Ranked among companies with meaningful Quick Ratio only.
LGND' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 1.61 Max: 12.87
Current: 10.73
0.26
12.87
Days Inventory 105.57
LGND's Days Inventory is ranked higher than
57% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 127.50 vs. LGND: 105.57 )
Ranked among companies with meaningful Days Inventory only.
LGND' s Days Inventory Range Over the Past 10 Years
Min: 33.18  Med: 79.07 Max: 151.94
Current: 105.57
33.18
151.94
Days Sales Outstanding 49.44
LGND's Days Sales Outstanding is ranked higher than
61% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. LGND: 49.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
LGND' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.79  Med: 31.32 Max: 146.43
Current: 49.44
5.79
146.43
Days Payable 172.46
LGND's Days Payable is ranked higher than
82% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 58.35 vs. LGND: 172.46 )
Ranked among companies with meaningful Days Payable only.
LGND' s Days Payable Range Over the Past 10 Years
Min: 197.62  Med: 282.10 Max: 822.72
Current: 172.46
197.62
822.72

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 26.17
LGND's Price/Tangible Book is ranked lower than
92% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. LGND: 26.17 )
Ranked among companies with meaningful Price/Tangible Book only.
LGND' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.02  Med: 20.27 Max: 206.67
Current: 26.17
6.02
206.67
Price/Projected FCF 6.14
LGND's Price/Projected FCF is ranked lower than
61% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. LGND: 6.14 )
Ranked among companies with meaningful Price/Projected FCF only.
LGND' s Price/Projected FCF Range Over the Past 10 Years
Min: 5.35  Med: 7.57 Max: 98.86
Current: 6.14
5.35
98.86
Price/Median PS Value 1.90
LGND's Price/Median PS Value is ranked lower than
81% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. LGND: 1.90 )
Ranked among companies with meaningful Price/Median PS Value only.
LGND' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 0.75 Max: 39.79
Current: 1.9
0.23
39.79
Price/Graham Number 3.42
LGND's Price/Graham Number is ranked lower than
52% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. LGND: 3.42 )
Ranked among companies with meaningful Price/Graham Number only.
LGND' s Price/Graham Number Range Over the Past 10 Years
Min: 1.56  Med: 1.92 Max: 2.98
Current: 3.42
1.56
2.98
Earnings Yield (Greenblatt) (%) 1.50
LGND's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. LGND: 1.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LGND' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 1.20 Max: 1.7
Current: 1.5
0.2
1.7

More Statistics

Revenue (TTM) (Mil) $86.96
EPS (TTM) $ 12.26
Beta0.95
Short Percentage of Float20.83%
52-Week Range $71.63 - 131.84
Shares Outstanding (Mil)20.82

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 119 156 214
EPS ($) 2.36 5.34 8.48
EPS without NRI ($) 2.36 5.34 8.48
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for LGND

Headlines

Articles On GuruFocus.com
RS Investment Increases Holdings in Ulta Salon, Noble Energy and Fortune Brands Dec 23 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 

More From Other Websites
3 Highly Rated IBD Stocks Powering A Top Biotech ETF’s Revival May 27 2016
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission... May 25 2016
LIGAND PHARMACEUTICALS INC Financials May 18 2016
VKTX: Phase 2 Study of VK5211 for Hip Fracture Ongoing; Phase 2 Study of VK2809 for... May 16 2016
Intec Pharma to Nominate Dr. John W. Kozarich as Chairman of the Board of Directors May 16 2016
ETF’s with exposure to Ligand Pharmaceuticals, Inc. : May 9, 2016 May 09 2016
LIGAND PHARMACEUTICALS INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement,... May 09 2016
Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q1, 2016 By the Numbers May 05 2016
Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View May 05 2016
IBD 50: Ligand Pharma Beats Q1 Estimates, Buys Device Royalties May 04 2016
Ligand (LGND) Beats Q1 Earnings and Revenue Estimates May 04 2016
Ligand Pharmaceuticals Q1 Adjusted Earnings Beat May 04 2016
Q1 2016 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open May 04 2016
Ligand tops 1Q revenue forecasts May 04 2016
Ligand tops 1Q revenue forecasts May 04 2016
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement May 04 2016
Ligand Reports First Quarter 2016 Financial Results May 04 2016
Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix® Cardiovascular... May 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)